The increasing incidence of endometrial cancer is placing greater emphasis on timely recognition of abnormal uterine bleeding, individualized risk assessment and prompt diagnostic evaluation.

For physicians, the clinical challenge is often not identifying a dramatic presentation but recognizing when a change in bleeding pattern warrants further workup.

Endometrial cancer arises from the endometrial lining and is distinct from other uterine malignancies, including uterine sarcomas. In a recent Baptist HealthTalk discussion, John P. Diaz, M.D., gynecologic oncologist at Baptist Health Herbert Wertheim Cancer Institute and chief of gynecologic oncology at Baptist Health, described endometrial cancer as the most common gynecologic malignancy and noted that incidence is rising in the United States and globally.

Dr. Diaz pointed to population aging and obesity as important contributors to that trend. He also emphasized that although most cases occur after menopause, endometrial cancer should remain in the differential diagnosis when younger or perimenopausal patients develop a new or unexplained pattern of abnormal bleeding.

Obesity, Estrogen Exposure and Clinical Risk

The association between obesity and endometrial cancer has an important endocrine component. Adipose tissue can contribute to estrogen production, and prolonged estrogenic stimulation of the endometrium may promote progression from precancerous changes to malignancy, Dr. Diaz explained.

Increasing age, obesity and comorbidities such as diabetes were among the risk factors highlighted in the discussion. These factors can help inform clinical suspicion, but Dr. Diaz stressed that symptom recognition remains central because there is no routine population screening test for endometrial cancer in average-risk patients.

Abnormal Uterine Bleeding Remains the Key Clinical Signal

Postmenopausal bleeding warrants evaluation regardless of volume, Dr. Diaz noted.

“Any postmenopausal bleeding is abnormal,” he said. “That doesn’t mean that it’s cancer, but any woman who has bleeding after menopause, even just spotting, needs to report that to her gynecologist.”

In premenopausal and perimenopausal patients, the assessment is more nuanced because cycle irregularity is common. The clinically relevant question is whether the patient has developed a meaningful change from her baseline pattern. Dr. Diaz cited intermenstrual bleeding, increasingly heavy menstrual flow and postcoital bleeding as examples that should prompt further evaluation. Pelvic pain, bloating and abnormal vaginal discharge may also occur.

Perimenopause can create a diagnostic blind spot when new bleeding is attributed reflexively to hormonal transition. Dr. Diaz emphasized that most abnormal bleeding will ultimately have a benign explanation, but it should not be presumed physiologic without appropriate assessment.

Diagnosis is Symptom-Driven and Requires Tissue

Initial evaluation may include a detailed bleeding history, pelvic examination and transvaginal ultrasound to assess the endometrial lining. Definitive diagnosis, however, requires histologic confirmation through endometrial tissue sampling.

"The only way to really diagnose it is with a tissue biopsy," Dr. Diaz said. Tissue sampling allows the pathologist to distinguish benign pathology from malignancy and helps establish the histologic information that informs subsequent management.

Histology and Stage Shape Treatment Intensity

Dr. Diaz identified endometrioid carcinoma as the most common subtype and described it as generally less aggressive, with many cases detected at a stage at which surgery alone may be sufficient. Serous and clear cell histologies, by contrast, may behave more aggressively and may present at more advanced stages.

For early-stage disease, hysterectomy remains central to treatment. Management of the fallopian tubes and ovaries can vary according to age and individual clinical circumstances. Patients with more advanced disease may require multimodality treatment that incorporates surgery, radiation therapy, chemotherapy, immunotherapy or a combination of approaches.

Immunotherapy is Expanding Options in Advanced Disease

One of the most consequential changes in the treatment landscape, according to Dr. Diaz, is the expanding role of immunotherapy. He contrasted current options with a period in which recurrent or advanced disease was managed primarily with chemotherapy and fewer effective alternatives were available.

The addition of immunotherapy has broadened systemic treatment strategies and, in his clinical experience, improved outcomes for some patients. Dr. Diaz also highlighted biomarker-directed therapies and antibody-drug conjugates as part of an increasingly individualized treatment landscape for advanced endometrial cancer.

Fertility-Sparing Management Requires Careful Selection

The occurrence of endometrial cancer in younger patients also raises questions about fertility preservation. In carefully selected patients with certain early-stage endometrioid cancers, Dr. Diaz described fertility-sparing options that may include local resection while preserving the uterus or progesterone-based therapy, including intrauterine delivery.

“They can preserve their uterus and, once we eliminate the risk of the endometrial cancer, they can go on to get pregnant in the future,” he said, noting that patients in his practice have subsequently delivered healthy babies.

Patient selection, oncologic safety and close surveillance are critical considerations when discussing a fertility-preserving approach.

Inherited Risk Should Remain Part of the Assessment

Family history can provide an additional signal. Dr. Diaz highlighted Lynch syndrome and the importance of recognizing family clustering of endometrial, colorectal and ovarian cancers.

Patients with a suggestive family history may warrant discussion of genetic evaluation.

Dr. Diaz also cautioned that direct-to-consumer testing may examine a more limited set of variants than comprehensive clinical testing, making appropriate clinical interpretation important.

Maintain a Low Threshold for Evaluating Unexplained Bleeding

The practical message for physicians is not that abnormal bleeding is synonymous with malignancy. Most abnormal bleeding will have another cause. The clinical priority is to avoid dismissing a meaningful change in bleeding pattern before an appropriate evaluation is completed.

Earlier diagnosis may allow surgery alone to be curative in selected patients, whereas delayed diagnosis can lead to more complex multimodality treatment. At the same time, the rapid evolution of immunotherapy and other systemic treatments is creating additional options for patients with advanced disease.